Julie A. Johnson, Pharm.D., FCCP, BCPS is Professor and Chair of Pharmacy Practice and Professor of Pharmaceutics and Medicine (Cardio-logy) at the University of Florida Colleges of Pharmacy and Medicine, and Director, University of Florida Center for Pharmacogenomics. She received her B.S. in Pharmacy from the Ohio State University and her Pharm.D. from the University of Texas at Austin and the University of Texas Health Science Center at San Antonio. She also completed a post-doctoral fellowship in cardiovascular pharmacology/pharmacokinetics at the Ohio State University.

Dr. Johnson is presently serving on the Nonprescription Drugs Advisory Committee of the FDA and a four year term on the Protocol Review Commit-tee for the NIH’s National Heart Lung Blood Institute Pediatric Heart Net-work. She also is currently serving on the Board of Regents of the American College of Clinical Pharmacy, the editorial board for the journals Pharmacogenetics and Pharmacotherapy and as manuscript reviewer for numerous other scientific journals of pharmacy and medicine.

Dr. Johnson’s research focus is cardiovascular drug pharmaco-genomics, and disease-gene associations that may be relevant to pharmacogenomics. She currently has studies ongoing in the areas of hypertension, heart failure, ischemic heart disease and obesity. The primary focus is on proteins that are drug targets and the impact their genetic polymorphisms on drug response and disease. Her research has been continuously funded by the National Institutes of Health and/or the American Heart Association since 1990.

About the lecture

β-Blocker Pharmacogenetics

Requires Windows Media Player to view lecture

"Pharmacogenetics is a field aimed at uncovering the April 24, 2007ecture will begin with an overview of the field and description of genetic and molecular biology terms that are important to understanding pharmacogenetics data. Dr. Johnson will then discuss the β1-adrenergic receptor polymorphisms, our current understanding of the effects of these polymorphisms on the protein’s function, and data associating the polymorphisms with resting hemodynamics and hypertension. Finally, Dr. Johnson will discuss recent data from her laboratory of the association between β1-adrenergic receptor polymorphisms and the antihypertensive response to β-blockers."

Quoted from the 2002-2003 Philip C. and Ethel F. Ashby Lecture Announcement Brochure.